title: [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
abstract: CKD is a common disease that is estimated to develop one in eight persons in Japan. The CKD itself is highly risk factor on the cardiac/vascular mortality. In addition,a new concept has been proposed "CKD-MBD". CKD-MBD is composed of a combination of abnormal mineral metabolism, abnormal bone, and extra skeletal calcification with cardiovascular high mortality. Treatment for CKD-MBD is a wide-ranging. We aim to decline cardiovascular event, fracture, and mortality rate of patients with CKD. The main therapeutic target for CKD-MBD becomes the phosphate control. Today, we can use of the VRDA, Calcimimetics and muti-phosphate binders as a lot of pharmacological intervention.
authors.affiliation: Department of Nephrology, Wakayama Medical University, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Iwashita
authors.affiliation: Department of Nephrology, Wakayama Medical University, Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Iwashita
authors.affiliation: Department of Nephrology, Faculty of Medicine, Shimane University, Japan.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Ito
authors.affiliation: Department of Nephrology, Wakayama Medical University, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigematsu
mesh_terms: D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism / Q000628:therapy*; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology; D057966:Calcimimetic Agents / Q000627:therapeutic use; D002114:Calcinosis; D002119:Calcium Carbonate / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology; D000069449:Cinacalcet / Q000627:therapeutic use; D005290:Ferric Compounds / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D008903:Minerals / Q000378:metabolism*; D016105:Parathyroidectomy; D010710:Phosphates / Q000378:metabolism; D016226:Phosphorus, Dietary / Q000008:administration & dosage; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D012307:Risk Factors; D000069603:Sevelamer / Q000627:therapeutic use
chemical_list: D057966:Calcimimetic Agents; D005290:Ferric Compounds; D008903:Minerals; D010710:Phosphates; D016226:Phosphorus, Dietary; C025314:ferric citrate; D000069603:Sevelamer; D002119:Calcium Carbonate; D000069449:Cinacalcet